FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roberto Pili

Research Profile

Disorders

Living Beings

Chemicals & Drugs

Anatomy

Tumor Cell Line

Procedures

Concepts & Ideas

Treatment Outcome

Physiology

Cell Proliferation

Co-author Network

Publications

TOP 3
Saby George; Roberto Pili
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
Subroto Chatterjee; Marc K Halushka; Nezar Alsaeedi; Veera Bandaru; Jennifer Hou; Georges Ndikuyeze; Roberto Pili; Lan Wu; Norman Haughey
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
Jonathan C Welti; David Robertson; Kevin Sharpe; Julie Soffe; Caroline J Springer; Antoinette van Weverwijk; Demelza Bird; Janine T Erler; Shane Foo; Julie Foster; Sophia Frentzas; Morgane Gourlaouen; Stephen J Mather; Roberto Pili; Thomas Powles; Natasha Preece; Andrew R Reynolds
Contrasting effects of sunitinib within in vivo models of metastasis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roberto Pili (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Saby George; Roberto Pili
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
Current oncology reports 2013;15(2):65-8.
2013: Subroto Chatterjee; Marc K Halushka; Nezar Alsaeedi; Veera Bandaru; Jennifer Hou; Georges Ndikuyeze; Roberto Pili; Lan Wu; Norman Haughey
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
PloS one 2013;8(5):e63726.
2012: Jonathan C Welti; David Robertson; Kevin Sharpe; Julie Soffe; Caroline J Springer; Antoinette van Weverwijk; Demelza Bird; Janine T Erler; Shane Foo; Julie Foster; Sophia Frentzas; Morgane Gourlaouen; Stephen J Mather; Roberto Pili; Thomas Powles; Natasha Preece; Andrew R Reynolds
Contrasting effects of sunitinib within in vivo models of metastasis.
Angiogenesis 2012;15(4):623-41.
2012: Rosalba Minelli; Piergiorgio Pettazzoni; Francesco Trotta; Giuseppina Barrera; Roberta Cavalli; Eric Ciamporcero; Chiara Dianzani; Leigh Ellis; Roberto Fantozzi; Roberto Pili
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2012;47(4):686-94.
2012: Michael J Morris; Roberto Pili; Dana Elizabeth Rathkopf; Howard I Scher; Susan F Slovin; M Vincent; J J Chudow; Samuel R Denmeade; Mario A Eisenberger; J Farrelly; Michael A Carducci
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(10):2714-9.
2012: Anthony W Tolcher; A Trinh; M Acharya; K N Chi; M Gonzalez; J J Jiao; T Kheoh; A Molina; C Pankras; Roberto Pili; N D Shore; N Tran
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology 2012;70(2):305-13.
2012: John M L Ebos; Roberto Pili
Mind the gap: potential for rebounds during antiangiogenic treatment breaks.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(14):3719-21.
2012: Daniel Keizman; Svetlana Kovel; Natalie Maimon; Avivit Peer; Roberto Pili; Avishay Sella; Victoria Sinibaldi; Mario A Eisenberger; Maya Gottfried; Hans-Joerg Hammers; Henry Hayat; Maya Ish-Shalom; Raanan Berger; Ben Boursi; Michael A Carducci
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 2012;48(7):1031-7.
2012: Leigh Ellis; Kristin Lehet; Remi Adelaiye; Swathi Ramakrishnan; Roberto Pili
Development of a castrate resistant transplant tumor model of prostate cancer.
The Prostate 2012;72(6):587-91.
2012: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Mark K. Buyyounouski; Michael A Carducci; Sam S Chang; Toni K Choueiri; Shilpa Gupta; Steven L Hancock; Gary R Hudes; Eric Jonasch; Timothy M Kuzel; Clayton Lau; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(4):502-35.
2012: Justine Yang Bruce; Michael A Carducci; Jens Eickhoff; Theodore Logan; Roberto Pili; Anthony Treston; George Wilding; Jamie Arnott; Glenn Liu
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Investigational new drugs 2012;30(2):794-802.
2012: Eunice S Wang; Roberto Pili; Mukund Seshadri
Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(7):760-1; author reply 761-3.
2012: Leigh Ellis; Hans-Joerg Hammers; Kristin Lehet; Mukund Seshadri; Preeti Shah; Paula Sotomayor; Gissou Azabdaftari; Roberto Pili
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Molecular cancer therapeutics 2012;11(2):383-92.
2012: Roberto Pili; Michael A Carducci; S Altiok; Ming Zhao; J Zwiebel; DI QIAN; Brenda Salumbides; M A Rudek
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
British journal of cancer 2012;106(1):77-84.
2012: Daniel Keizman; Svetlana Kovel; Natalie Maimon; Avivit Neumann; Avivit Peer; Roberto Pili; Eli Rosenbaum; Michael A Carducci; Mario A Eisenberger; Maya Gottfried; Hans-Joerg Hammers; Maya Ish-Shalom; Victoria Sinibaldi; Avishay Sella
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
The oncologist 2012;17(12):1508-14.
2012: Sreenivasulu Chintala; Farukh A Durrani; Tanbir Najrana; Roberto Pili; Shousong Cao; Karoly Toth; Youcef M Rustum
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
BMC cancer 2012;12():293.
2012: Li Shen; Protul Shrikant; Paula Sotomayor; Swathi Ramakrishnan; Michael Ciesielski; Leigh Ellis; Robert A Fenstermaker; Kiersten M Miles; Roberto Pili
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
PloS one 2012;7(1):e30815.
2012: Daniel Keizman; Hans-Joerg Hammers; Peng Huang; Maya Ish-Shalom; Roberto Pili; Mario A Eisenberger; Michael A Carducci
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 2012;48(2):202-8.
2011: Kristy J Gotink; Richard R de Haas; Henk Dekker; Henk J Broxterman; Laurens V Beerepoot; Arjan W Griffioen; Godefridus J Peters; Mariette Labots; Yehuda G Assaraf; Richard J Honeywell; René J Musters; Roberto Pili; Gerrit Jansen; Michelle A Rudek; Hendrik Verheul
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(23):7337-46.
2011: Michael R Harrison; KyungMann Kim; Jamie Arnott; Noah M Hahn; Hans-Joerg Hammers; William K Oh; Scott Perlman; Roberto Pili; Carolyn Sidor; Christopher Sweeney; George Wilding; Glenn Liu
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
Investigational new drugs 2011;29(6):1465-74.
2011: Roberto Pili; Walter M Stadler; Vasileios J Assikis; Anders Björk; Michael A Carducci; Goran Forsberg; Jeffrey R Gingrich; Michael Häggman; Orjan Nordle; Andrew J Armstrong
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(30):4022-8.
2011: Piergiorgio Pettazzoni; Roberto Pili; Stefania Pizzimenti; Cristina Toaldo; Koji Uchida; Eric Ciamporcero; Federica Dal Bello; Mario Umberto Dianzani; Claudio Medana; Rosalba Minelli; Valerio Giacomo Minero; Giuseppina Barrera
Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells.
Free radical biology & medicine 2011;51(8):1610-8.
2011: Saby George; Michael A Carducci; Roberto Pili; Jenny J Kim
Role of immunotherapy for renal cell cancer in 2011.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(9):1011-8.
2011: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Philippe E Spiess; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Michael A Carducci; Sam S Chang; Toni K Choueiri; Steven L Hancock; Gary R Hudes; Eric Jonasch; David Josephson; Timothy M Kuzel; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(9):960-77.
2011: Rebecca L O'Malley; Roberto Pili; Katherine A Brewer; Matthew H Hayn; Hyung L Kim; Willie Underwood; Thomas Schwaab
Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?
Urology 2011;78(3):595-600.
2011: Daniel Keizman; Jenny J Kim; Roberto Pili; Emmanuel S Antonarakis; Mario A Eisenberger; Hans-Joerg Hammers; Peng Huang; Michael A Carducci
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.
European journal of cancer (Oxford, England : 1990) 2011;47(13):1955-61.
2011: Thomas Schwaab; Roberto Pili
Provenge: combating prostate cancer with a vengeance?
Expert review of vaccines 2011;10(8):1113-4.
2011: Ila Tamaskar; Jaspreet Dhillon; Roberto Pili
Resistance to angiogenesis inhibitors in renal cell carcinoma.
Clinical advances in hematology & oncology : H&O 2011;9(2):101-10.
2011: Gary R Hudes; Michael A Carducci; Toni K Choueiri; Peg Esper; Eric Jonasch; Rashmi Kumar; Kim A Margolin; M Dror Michaelson; Robert J Motzer; Roberto Pili; Susan Roethke; Sandy Srinivas
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9 Suppl 1():S1-29.
2011: Lee P Resta; Roberto Pili; Mario A Eisenberger; Avery Spitz; Serina King; Jennifer Porter; Amy Franke; Ramesh Boinpally; Michael A Carducci; Christopher J Sweeney
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Cancer chemotherapy and pharmacology 2011;67(2):431-8.
2011: Piergiorgio Pettazzoni; Stefania Pizzimenti; Cristina Toaldo; Paula Sotomayor; Luigina Tagliavacca; Song Liu; Dan Wang; Rosalba Minelli; Leigh Ellis; Peter Atadja; Eric Ciamporcero; Mario Umberto Dianzani; Giuseppina Barrera; Roberto Pili
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Free radical biology & medicine 2011;50(2):313-22.
2011: Leigh Ellis; Kristin Lehet; Song Liu; Kiersten M Miles; Remi Adelaiye; Peter Atadja; Michael A Carducci; Swathi Ramakrishnan; Dan Wang; Roberto Pili
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
PloS one 2011;6(11):e27178.
2010: Roberto Pili
Is this a true renaissance for the treatment of prostate cancer?
Oncology (Williston Park, N.Y.) 2010;24(14):1327-8.
2010: Daniel Keizman; Marianna Zahurak; Victoria Sinibaldi; Michael A Carducci; Samuel R Denmeade; Charles G Drake; Roberto Pili; Emmanuel S Antonarakis; Susan Hudock; Mario A Eisenberger
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5269-76.
2010: CLAIRE SNYDER; Amanda Blackford; Julie R Brahmer; Michael A Carducci; Roberto Pili; Vered Stearns; Antonio C Wolff; Sydney M Dy; Albert W Wu
Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2010;19(6):837-45.
2010: Hans-Joerg Hammers; Hendrik Verheul; Brenda Salumbides; Rajni Sharma; MICHELLE RUDEK-RENAUT; Janneke Jaspers; Preeti Shah; Leigh Ellis; Li Shen; Silvia Paesante; Karl Dykema; Kyle A Furge; Bin Tean Teh; GEORGES NETTO; Roberto Pili
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Molecular cancer therapeutics 2010;9(6):1525-35.
2010: Roberto Pili; Mark A Rosenthal; Paul N Mainwaring; Guy Van Hazel; Sandy Srinivas; Robert Dreicer; SANJAY GOEL; Joseph Leach; Shirley Wong; Peter Clingan
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(10):2906-14.
2010: Hendrik Verheul; Karen van Erp; Marjolein Y V Homs; G S Yoon; Petra van Der Groep; Craig Rogers; Donna E Hansel; GEORGES NETTO; Roberto Pili
The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma.
Urology 2010;75(3):608-14.
2010: Jacob E Koskimaki; Emmanouil D Karagiannis; Benjamin Tang; Hans-Joerg Hammers; D Neil Watkins; Roberto Pili; Aleksander S Popel
Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model.
BMC cancer 2010;10():29.
2009: Brenda Salumbides; Kristin M Lehet; Georges Ndikuyeze; Roberto Pili
Pre-clinical models of renal carcinoma and their utility in drug development.
Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] 2009;Chapter 14():Unit 14.13.
2009: Ila Tamaskar; Roberto Pili
Update on novel agents in renal cell carcinoma.
Expert review of anticancer therapy 2009;9(12):1817-27.
2009: Deborah Bradley; Dana Elizabeth Rathkopf; Rodney Dunn; Walter M Stadler; Glenn Liu; David C Smith; Roberto Pili; James Zwiebel; Howard I Scher; Maha Hussain
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
Cancer 2009;115(23):5541-9.
2009: CLAIRE SNYDER; Elizabeth Garrett-Mayer; Amanda L Blackford; Julie R Brahmer; Michael A Carducci; Roberto Pili; Vered Stearns; Antonio C Wolff; Sydney M Dy; Albert W Wu
Concordance of cancer patients' function, symptoms, and supportive care needs.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2009;18(8):991-8.
2009: David J Vaughn; Sandy Srinivas; Walter M Stadler; Roberto Pili; Daniel Petrylak; Cora N Sternberg; David C Smith; Sarah Ringuette; Edwin de Wit; Virginie Pautret; Claude George
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
Cancer 2009;115(18):4110-7.
2009: Leigh Ellis; Hans-Joerg Hammers; Roberto Pili
Targeting tumor angiogenesis with histone deacetylase inhibitors.
Cancer letters 2009;280(2):145-53.
2009: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia del Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3584-90.
2009: Antonina Kolmakova; Mohanraj Rajesh; David Zang; Roberto Pili; Subroto Chatterjee
VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo.
Glycoconjugate journal 2009;26(5):547-58.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):618-30.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):672-93.
2009: Roberto Pili
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Clinical advances in hematology & oncology : H&O 2009;7(4):252-4.
2008: Huafeng Zhang; Zheng (David) Qian; Yee Sun Tan; Kangae Lee; Ping Gao; yunzhao richard ren; Sergio Rey; Hans-Joerg Hammers; Daniel Chang; Roberto Pili; Chi Dang; Jun O Liu; Gregg L Semenza
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(50):19579-86.
2008: Elisabeth Iljas Heath; David W Hillman; Ulka Nitin Vaishampayan; Shijie Sheng; Asfar S Azmi; Felicity WK Harper; Melvin Gaskins; Henry C Pitot; Winston Tan; S Percy Ivy; Roberto Pili; Michael A Carducci; Charles Erlichman; Glenn Liu
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7940-6.
2008: MARTIN LODGE; Heather A Jacene; Roberto Pili; Richard L Wahl
Reproducibility of tumor blood flow quantification with 15O-water PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(10):1620-7.
2008: Dana Elizabeth Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):2959-65.
2008: Hendrik Verheul; Brenda Salumbides; Karen Van Erp; Hans-Joerg Hammers; Zheng (David) Qian; Tolib B Sanni; Peter Atadja; Roberto Pili
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3589-97.
2008: CLAIRE SNYDER; Elizabeth Garrett-Mayer; Julie R Brahmer; Michael A Carducci; Roberto Pili; Vered Stearns; Antonio C Wolff; Sydney M Dy; Albert W Wu
Symptoms, supportive care needs, and function in cancer patients: how are they related?
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2008;17(5):665-77.
2008: Lillian L Siu; Roberto Pili; Ignacio Duran; Wells A Messersmith; Eric X Chen; Rana Sullivan; Martha Maclean; Serina King; Shirley Brown; Gregory K Reid; Zuomei Li; Ann M Kalita; Eric J Laille; Jeffrey M Besterman; Robert E Martell; Michael A Carducci
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1940-7.
2008: Jing Li; Michael B Jameson; Bruce C Baguley; Roberto Pili; Sharyn D Baker
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(7):2102-10.
2008: Quan Dong Nguyen; Syed Mahmood Shah; Gulnar Hafiz; Diana V Do; Julia A Haller; Roberto Pili; Ingrid Zimmer-Galler; Kashif Janjua; R C Andrew Symons; Peter A Campochiaro
Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.
American journal of ophthalmology 2008;145(2):257-266.
2008: Li Shen; Roberto Pili
Posttranscription regulation of prostate cancer growth.
Cancer journal (Sudbury, Mass.) 2008;14(1):46-53.
2007: Hendrik Verheul; Martijn Lolkema; Zheng (David) Qian; Yvonne H A Hilkes; Eleni Liapi; Jan-Willem N Akkerman; Roberto Pili; Emile E Voest
Platelets take up the monoclonal antibody bevacizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5341-7.
2007: Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria Sinibaldi; JANET WALCZAK; Samuel R Denmeade
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer biology & therapy 2007;6(9):1360-7.
2007: Yukihiko Kato; Kiyoshi Yoshimura; Tae Kwang Shin; Hendrik Verheul; Hans-Joerg Hammers; Tolib B Sanni; Brenda Salumbides; Karen Van Erp; Richard D Schulick; Roberto Pili
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4538-46.
2007: Zheng (David) Qian; Yong-Feng Wei; Xiaofei Wang; Yukihiko Kato; Linzhao Cheng; Roberto Pili
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
The Prostate 2007;67(11):1182-93.
2007: Hendrik Verheul; Zheng (David) Qian; Michael A Carducci; Roberto Pili
Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Cancer chemotherapy and pharmacology 2007;60(3):329-39.
2007: Hendrik Verheul; Hans-Joerg Hammers; Karen van Erp; Yonfeng Wei; Tolib B Sanni; Brenda Salumbides; Zheng (David) Qian; George D Yancopoulos; Roberto Pili
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4201-8.
2007: Gopal K Bajaj; Zhe Zhang; Elizabeth Garrett-Mayer; Renee Drew; Victoria Sinibaldi; Roberto Pili; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Theodore L DeWeese
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Urology 2007;69(3):526-31.
2007: Ming Zhao; MICHELLE RUDEK-RENAUT; Aleksandr Mnasakanyan; Carol Hartke; Roberto Pili; Sharyn D Baker
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.
Journal of pharmaceutical and biomedical analysis 2007;43(2):784-7.
2007: Sushant Kachhap; Dennis Faith; Zheng (David) Qian; Shabana Shabbeer; Nathan L Galloway; Roberto Pili; Samuel R Denmeade; Angelo M DeMarzo; Michael A Carducci
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.
PloS one 2007;2(9):e844.
2007: Yukihiko Kato; Brenda Salumbides; Xiao-Fei Wang; Zheng (David) Qian; Simon Williams; Yongfeng Wei; Tolib B Sanni; Peter Atadja; Roberto Pili
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Molecular cancer therapeutics 2007;6(1):70-81.
2006: John T Isaacs; Roberto Pili; Zheng (David) Qian; Susan L Dalrymple; Jason B Garrison; Natasha Kyprianou; Anders Björk; Anders Olsson; Tomas Leanderson
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
The Prostate 2006;66(16):1768-78.
2006: Zheng (David) Qian; Sushant Kachhap; Spencer J Collis; Hendrik Verheul; Michael A Carducci; Peter Atadja; Roberto Pili
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.
Cancer research 2006;66(17):8814-21.
2006: Michael A Carducci; Luna Musib; Merrill S Kies; Roberto Pili; Mylene Truong; Julie R Brahmer; Patricia Cole; Rana Sullivan; Jeanne Riddle; Jill Schmidt; Nathan Enas; Vikram Sinha; Donald E Thornton; Roy S Herbst
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4092-9.
2006: Victoria Sinibaldi; Kathy Elza-Brown; Jill Schmidt; Mario A Eisenberger; Eli Rosenbaum; Samuel R Denmeade; Roberto Pili; JANET WALCZAK; Sharyn D Baker; Marianna Zahurak; Michael A Carducci
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
American journal of clinical oncology 2006;29(4):395-8.
2006: Curtis R Chong; Zheng (David) Qian; Fan Pan; Yongfeng Wei; Roberto Pili; David Sullivan; Jun O Liu
Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.
Journal of medicinal chemistry 2006;49(9):2677-80.
2006: Zheng (David) Qian; Yukihiko Kato; Shabana Shabbeer; Yongfeng Wei; Hendrik Verheul; Brenda Salumbides; Tolib B Sanni; Peter Atadja; Roberto Pili
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):634-42.
2005: Elisabeth Iljas Heath; Melvin Gaskins; Henry C Pitot; Roberto Pili; Winston Tan; Robert Marschke; Glenn Liu; David Hillman; Asfar S Azmi; Shijie Sheng; Charles Erlichman; Percy Ivy
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Clinical prostate cancer 2005;4(2):138-41.
2005: Richard E Link; Mohamad E Allaf; Roberto Pili; Louis R Kavoussi
Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5762-73.
2005: Eli Rosenbaum; Marianna Zahurak; Victoria Sinibaldi; Michael A Carducci; Roberto Pili; Menachem Laufer; Theodore L DeWeese; Mario A Eisenberger
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4437-43.
2005: Zheng (David) Qian; Mingqiang Ren; Yongfeng Wei; Xiaofei Wang; Fleur van de Geijn; Camilla Rasmussen; Osamu Nakanishi; Nicoletta Sacchi; Roberto Pili
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
The Prostate 2005;64(1):20-8.
2005: Xiao-Fei Wang; Zheng (David) Qian; Mingqiang Ren; Yukihiko Kato; Yongfeng Wei; Lu Zhang; Zoya Fansler; Douglas P Clark; Osamu Nakanishi; Roberto Pili
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3535-42.
2005: Robert J Motzer; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Philip Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Roberto Pili; Kamal S Pohar; Bruce G Redman; Sylvia Richey; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld; Donald A Urban
Kidney cancer. Clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(1):84-93.
2005: Kuo-Shyan Lin; Andrew Luu; Kwamena Baidoo; Hossein Hashemzadeh-Gargari; Ming-Kai Chen; Kenneth Brenneman; Roberto Pili; Martin G Pomper; Michael A Carducci; Henry N Wagner
A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation.
Bioconjugate chemistry 2005;16(1):43-50.
2004: Kuo-Shyan Lin; Andrew Luu; Kwamena Baidoo; Hossein Hashemzadeh-Gargari; Ming-Kai Chen; Roberto Pili; Martin G Pomper; Michael A Carducci; Henry N Wagner
A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
Bioconjugate chemistry 2004;15(6):1416-23.
2004: Zheng (David) Qian; Xiaofei Wang; Sushant Kachhap; Yukihiko Kato; Yongfeng Wei; Lu Zhang; Peter Atadja; Roberto Pili
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Cancer research 2004;64(18):6626-34.
2004: Judith E Karp; Ivana Gojo; Roberto Pili; Christopher D Gocke; Jacqueline Greer; Chuanfa Guo; Zheng (David) Qian; Lawrence Morris; Michael L Tidwell; Helen Chen; James Zwiebel
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3577-85.
2004: Usha Sunkara; JANET WALCZAK; Lori Summerson; Theresa Rogers; Mario A Eisenberger; Samuel R Denmeade; Roberto Pili; Carol Ann Huff; Victoria Sinibaldi; Michael A Carducci
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(1):37-41.
2003: Bruce Ruggeri; Jasbir Singh; Diane E Gingrich; Thelma S Angeles; Albom Mark; Shi Yang; Hong Chang; Candy Robinson; Kathryn Hunter; Pawel Dobrzanski; Susan Jones-Bolin; Sonya Pritchard; Lisa D Aimone; Andres Klein-Szanto; Jean-Marc Herbert; Francoise Bono; Paul Schaeffer; Pierre Casellas; Bernard Bourie; Roberto Pili; John T Isaacs; Mark A Ator; Robert L Hudkins; Jeffry L Vaught; John Mallamo; Craig Dionne
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Cancer research 2003;63(18):5978-91.
2003: Roberto Pili; Ross C Donehower
Is HIF-1 alpha a valid therapeutic target?
Journal of the National Cancer Institute 2003;95(7):498-9.
2002: Olga V Volpert; Roberto Pili; Hashmat A Sikder; Thomas Nelius; Tetiana Zaichuk; Chad Morris; Clinton B Shiflett; Meghann K Devlin; Katherine Conant; Rhoda M Alani
Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1.
Cancer cell 2002;2(6):473-83.
2002: Silvia M Sirchia; Mingqiang Ren; Roberto Pili; Elena Sironi; Giulia Somenzi; Riccardo Ghidoni; Salvatore Toma; Guido Nicolò; Nicoletta Sacchi
Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.
Cancer research 2002;62(9):2455-61.
2001: Saeed R Khan; Annastasiah Mhaka; Roberto Pili; John T Isaacs
Modified synthesis and antiangiogenic activity of linomide.
Bioorganic & medicinal chemistry letters 2001;11(4):451-2.
2001: Roberto Pili; M P Kruszewski; B W Hager; J Lantz; Michael A Carducci
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
Cancer research 2001;61(4):1477-85.
1997: Roberto Pili; J Chang; J Muhlhauser; Helen-Ann Brown Epstein; Maurizio C Capogrossi; Antonino Passaniti
Adenovirus-mediated gene transfer of fibroblast growth factor-1: angiogenesis and tumorigenicity in nude mice.
International journal of cancer. Journal international du cancer 1997;73(2):258-63.
1995: J Mühlhauser; Marsha J Merrill; Roberto Pili; H Maeda; M Bacic; B Bewig; Antonino Passaniti; N A Edwards; Helen-Ann Brown Epstein; Maurizio C Capogrossi
VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo.
Circulation research 1995;77(6):1077-86.
1995: corrado cirielli; Teresa Riccioni; C Yang; Roberto Pili; T Gloe; J Chang; K Inyaku; Antonino Passaniti; Maurizio C Capogrossi
Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo.
International journal of cancer. Journal international du cancer 1995;63(5):673-9.
1995: J Mühlhauser; Roberto Pili; Marsha J Merrill; H Maeda; Antonino Passaniti; Helen-Ann Brown Epstein; Maurizio C Capogrossi
In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor.
Human gene therapy 1995;6(11):1457-65.
1995: Roberto Pili; J Chang; R A Partis; R A Mueller; Francis J Chrest; Antonino Passaniti
The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth.
Cancer research 1995;55(13):2920-6.
1994: Roy C Ziegelstein; stefano corda; Roberto Pili; Antonino Passaniti; D Lefer; Jay L Zweier; A Fraticelli; Maurizio C Capogrossi
Initial contact and subsequent adhesion of human neutrophils or monocytes to human aortic endothelial cells releases an endothelial intracellular calcium store.
Circulation 1994;90(4):1899-907.
1994: Roberto Pili; Y Guo; J Chang; H Nakanishi; G R Martin; Antonino Passaniti
Altered angiogenesis underlying age-dependent changes in tumor growth.
Journal of the National Cancer Institute 1994;86(17):1303-14.
1994: Roy C Ziegelstein; Harold A Spurgeon; Roberto Pili; Antonino Passaniti; Linda Cheng; stefano corda; Edward G Lakatta; Maurizio C Capogrossi
A functional ryanodine-sensitive intracellular Ca2+ store is present in vascular endothelial cells.
Circulation research 1994;74(1):151-6.
1994: Y Guo; Roberto Pili; Antonino Passaniti
Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix.
The Prostate 1994;24(1):1-10.
1993: Roberto Pili; stefano corda; Antonino Passaniti; Roy C Ziegelstein; Alan Heldman; Maurizio C Capogrossi
Endothelial cell Ca2+ increases upon tumor cell contact and modulates cell-cell adhesion.
The Journal of clinical investigation 1993;92(6):3017-22.
1993: Carlo Bartoloni; Luisa Guidi; Roberto Pili; Z A Lewis; A Tricerri; F Cursi; Nicola Gentiloni; E Cortesi; G Gambassi
Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients.
Oncology 1993;50(1):27-34.
1992: Antonino Passaniti; R M Taylor; Roberto Pili; Y Guo; P V Long; J A Haney; R R Pauly; D S Grant; G R Martin
A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
Laboratory investigation; a journal of technical methods and pathology 1992;67(4):519-28.
1992: Carlo Bartoloni; Luisa Guidi; A Tricerri; F Patriarca; Roberto Pili; F Cursi; M Canetta; A Cappelli; M Vangeli; F Salvati
Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours'.
Oncology 1992;49(6):426-30.
1991: Luisa Guidi; Carlo Bartoloni; Daniela Frasca; L Antico; Roberto Pili; F Cursi; E Tempesta; C Rumi; E Menini; P Carbonin
Impairment of lymphocyte activities in depressed aged subjects.
Mechanisms of ageing and development 1991;60(1):13-24.
1991: Carlo Bartoloni; Luisa Guidi; Daniela Frasca; L Antico; Roberto Pili; F Cursi; A Di Giovanni; C Rumi; E Menini; P Carbonin
Immune parameters in a population of institutionalized elderly subjects: influence of depressive disorders and endocrinological correlations.
Mechanisms of ageing and development 1991;60(1):1-12.
1991: Carlo Bartoloni; Luisa Guidi; L Antico; C M Pariante; A Di Giovanni; Roberto Pili; F Cursi; A Tricerri; E Tempesta; Daniela Frasca
Psychological status and immunological parameters of institutionalized aged.
Panminerva medica 1991;33(3):164-9.
1991: Luisa Guidi; Carlo Bartoloni; P Pellicanò; A Cappelli; F Cursi; Roberto Pili; A Tricerri; F Patriarca; G Gambassi
[Evaluation of latent changes in blood coagulation by the determination of plasma thrombin-antithrombin complex in gastrointestinal neoplasms].
La Clinica terapeutica 1991;136(6):367-73.
1990: Carlo Bartoloni; Luisa Guidi; L Antico; Roberto Pili; F Cursi; P Carbonin; G Gambassi; C Rumi; A Di Giovanni; G Menichella
Psychological status of institutionalized aged: influences on immune parameters and endocrinological correlates.
The International journal of neuroscience 1990;51(3-4):279-81.